While the prevalence of osteoporosis is growing rapidly with population aging, therapeutic options remain limited. Here, we identify potentially novel roles for Ca V 1.2 L-type voltagegated Ca 2+ channels in osteogenesis and exploit a transgenic gain-of-function mutant Ca V 1.2 to stem bone loss in ovariectomized female mice. We show that endogenous Ca V 1.2 is expressed in developing bone within proliferating chondrocytes and osteoblasts.
Introduction
Ca V 1.2, an L-type voltage-gated Ca 2+ channel, plays essential roles in many excitable cells, including neurons, smooth and cardiac muscle cells, and endocrine cells (1) . Upon membrane depolarization, Ca 2+ influx through the activated Ca V 1.2 channel triggers a wide range of physiological processes, such as excitation-contraction coupling in cardiac muscle cells, graded contraction in smooth muscle cells of the vasculature and gut, hormone secretion in endocrine tissue, postsynaptic responses in various neurons, and activation of gene expression paradigms across a variety of tissues. Common to all of these examples is that the excitable cells in which they occur support frequent and dynamic changes in membrane potential that facilitate activation of the voltage-gated Ca V 1.2 channel. In contrast, roles for Ca V 1.2 signaling in nonexcitable cells are not well understood, but a gain-of-function mutation (G406R) in the human CACNA1C gene, encoding the pore-forming α 1C subunit of Ca V 1.2, causes Timothy syndrome (TS) (2) and reveals prominent but previously unappreciated roles for Ca V 1.2 in nonexcitable tissue (3) .
TS is a multisystem disorder marked by life-threatening cardiac arrhythmias and soft-tissue syndactyly. The G406R mutation in Ca V 1.2 that causes TS reduces voltage-dependent inactivation, thus impairing channel closure and allowing more Ca 2+ influx into the cell. This increased Ca 2+ entry, and consequent delay of membrane repolarization, provides a clear rationale for the cardiac arrhythmias. How Ca V 1.2 participates in limb development and specifically why the mutant channel causes syndactyly, however, are not known. Some other variably penetrant features of TS, such as craniofacial and dental abnormalities and delayed hair development, demonstrate that a broad array of tissues are affected by aberrant Ca 2+ influx through Ca V 1.2 and reveal other unexpected but critical roles of Ca V 1.2 in nonexcitable tissues.
While the prevalence of osteoporosis is growing rapidly with population aging, therapeutic options remain limited. Here, we identify potentially novel roles for Ca V 1.2 L-type voltage-gated Ca 2+ channels in osteogenesis and exploit a transgenic gain-of-function mutant Ca V 1.2 to stem bone loss in ovariectomized female mice. We show that endogenous Ca V 1.2 is expressed in developing bone within proliferating chondrocytes and osteoblasts. Using primary BM stromal cell (BMSC) cultures, we found that Ca 2+ influx through Ca V 1.2 activates osteogenic transcriptional programs and promotes mineralization. We used Prx1-, Col2a1-, or Col1a1-Cre drivers to express an inactivationdeficient Ca V 1.2 mutant in chondrogenic and/or osteogenic precursors in vivo and found that the resulting increased Ca 2+ influx markedly thickened bone not only by promoting osteogenesis, but also by inhibiting osteoclast activity through increased osteoprotegerin secretion from osteoblasts. Activating the Ca V 1.2 mutant in osteoblasts at the time of ovariectomy stemmed bone loss. Together, these data highlight roles for Ca V 1.2 in bone and demonstrate the potential dual anabolic and anticatabolic therapeutic actions of tissue-specific Ca V 1.2 activation in osteoblasts.
In a previous study, increased Ca 2+ influx through the TS-mutant Ca V 1.2 (Ca V 1.2 TS ) channel in mandibular chondrocytes was shown in zebrafish and mouse models to recapitulate the macrognathia observed in TS patients (4) . As the mandible is unique among skeletal elements in the skull to derive from endochondral ossification, we hypothesized that Ca V 1.2 may influence bone development more broadly. Indeed, while plasma membranes of bone cells (e.g., osteoblasts) have not been shown to prominently display the voltage-dependent changes that control Ca V 1.2 activity in excitable tissue, earlier reports identified functional L-type Ca 2+ channels, mainly Ca V 1.2, in human mesenchymal stem cells from BM cultured in osteogenic medium (5), in osteosarcoma cell lines (6) , and in a rat osteoblast-like cell line (7) . Further, Ca V 1.2 was shown in an osteosarcoma cell line to be the primary site for Ca 2+ influx, which promoted osteoblast differentiation (8, 9) . In addition, Ca V 1.2 expression and channel activity were regulated by calciotropic hormones such as 1,25(OH) 2 D 3 (8, 10) and parathyroid hormone (11) , suggesting a functional contribution of Ca V 1.2 L-type Ca 2+ channel to bone development. More recently, a mutation in CACNA1C causing reduced current density through Ca V 1.2 was associated with osteopenia (12) .
Because Ca V 1.2 is a well-characterized pharmacological target, for which antagonists are widely used to treat hypertension, angina, and cardiac arrhythmias, we set out to explore Ca V 1.2 contributions to bone development and the consequent therapeutic potential of modulating Ca V 1.2 activity in bone. We characterized the expression profile of Ca V +/-mice are viable and fertile without obvious differences in any aspect of development (13) and only minor differences in morphology (4) . The lacZ expression in Ca V 1.2 +/lacZ mice thereby provides an accurate picture of the temporospatial Ca V 1.2 expression pattern during development and definitive identification of Ca V 1.2-expressing cells. We performed X-gal staining on frozen sections of long bones from early postnatal mice (P10), in which we observed strong staining in the resting and proliferating chondrocytes, but we did not detect staining in the hypertrophic chondrocytes ( Figure 1 , A-C). Expression was also strong in the perichondrium/periosteum (Figure 1, A and D) , and extensive staining appeared in the lining cells of trabecular bones underneath the growth plate ( Figure 1 , A and E). At a later postnatal stage (P18), we also observed significant staining in the endosteum ( Figure 1F ). This staining pattern suggested that at least some of Ca V 2+ channel blockers, diltiazem and nifedipine, applied to the cultures 12 hours before adding differentiation media. Cells were then cultured with the channel blocker or their diluents throughout the differentiation process. After 14 days of culture in osteogenic media, BMSCs treated with a channel blocker displayed substantially reduced mineralized nodule formation, as shown by von Kossa staining ( Figure 1H ). Quantitative PCR (qPCR) revealed that, in cells treated with the channel blocker, there was a marked decrease in transcripts of several osteoblast markers, including Alpl, Ibsp, and Bglap ( Figure 1I ). Together, these data suggest that Ca 2+ signaling through endogenous Ca V 1.2 regulates osteogenesis. Since the Prx1-Cre driver activated Ca V 1.2 TS expression during skeletal development, we next assessed whether we were able to detect the increase in bone mass in embryonic stage. Indeed, at P0, histology confirmed that Prx1-Cre;Ca V 1.2 TS femurs possessed a thicker bone collar and higher bone mass in the presumptive marrow cavity compared with littermate controls (Figure 2, G TS expressing (infected with Cre) BMSCs after 10 days of differentiation, a time when there was limited mineralization in the control (infected with GFP) BMSCs ( Figure 3C ). We explored the mechanisms driving the accelerated mineralization in BMSCs expressing Ca V 1. Figure 4A and Supplemental Figure 3C ). Quantitative analysis showed that osteoclast number per tissue area (Oc. N/T. Ar) was decreased by 55% and osteoclast area per tissue area (Oc. Ar/T. Ar) decreased by 54% in Prx1-Cre;Ca V -expressing (Ad-Cre) BMSCs at D0 (6 hours of differentiation) or after 2, 10 and 17 days (D2, D10, and D17) of differentiation. Bar values are means ± SD (n = 3. *P < 0.05 and **P < 0.01). Statistical analysis was performed by 2-tailed unpaired t test, and a P value less than 0.05 was considered significant.
Increased
( Figure 4C and Supplemental Figure 3C ). We further examined whether Ca V 1.2 TS affects the Rankl/Opg (Tnfs11/Tnfrsf11b) mRNA expression ratio in primary BMSC cultures after activating Ca V 1.2 TS expression and found -consistent with the in vivo data -a 61% decrease in Ca V 1.2 TS -expressing BMSCs ( Figure  4D ). Additionally, we cocultured BM-derived macrophages (BMMs) with Ca V 1.2 TS -expressing or WT calvarial osteoblasts in the presence of 1,25-dihydroxyvitamin D3 and prostaglandin E 2 and observed less TRAP-positive osteoclasts with osteoblasts expressing the Ca V Figure 4A) . Quantitative measurement showed that BV/TV was increased by 56% in Sp7-Cre;Ca V 1.2 TS male mice after activating Ca V 1.2 TS expression for 8 weeks. This increase in bone acquisition was characterized by significant increase in trabecular thickness (Tb.Th) and trabecular number (Tb.N), whereas trabecular bone separation (Tb.Sp) was unaffected (Supplemental Figure 4B) .
We then tested whether expression of Ca V 1.2 TS in postnatal bone could prevent estrogen deficiency-induced bone loss in female mice. We performed OVX on 2-month-old Sp7-Cre;Ca V Statistical analysis was performed by 2-tailed unpaired t test, and a P value less than 0.05 was considered significant. normal in these mice (Supplemental Figure 5) , suggesting that depleting estrogen or activating Ca V 1.2 TS expression at the 2-month-old time point does not affect the growth plate and the longitudinal growth of long bones. In the Cre -controls subject to OVX, we observed noticeable trabecular bone loss (compared with sham controls) 8 weeks after OVX (Figure 5A) . Quantitative measurements showed that 43% of BV/TV was lost in control mice after OVX ( Figure 5B), consistent with less trabecular bones shown in H&E staining ( Figure 5C ). Compared with sham-operated control mice, the parameter Tb.Th remained relatively constant in OVX mice throughout the 8-week experimental period, while Tb.N decreased and Tb.Sp increased after OVX surgery ( Figure 5B ), indicating that OVX can induce loss of trabecular bone by perforation and division, as seen in previous OVX experiments (22, 23) . Dynamic histomorphometric analysis showed that bone formation rate (BFR) was decreased by 71%, mineral apposition rate (MAR) was decreased by 49%, and the percentage of mineralizing surface over bone surface (MS/BS) was decreased by 38% in the control group after OVX ( Figure 5, D and E) , indicating reduced osteoblast function after estrogen deficiency at 2 months of age. In contrast, activation of Ca V 1.2 TS (by removing doxycycline) at the time of surgery effectively mitigated bone loss and maintained bone mass after OVX (BV/TV, 4.25% ± 0.54%) to the same level as that in the sham-operated controls (BV/TV, 4.49% ± 0.33%) ( Figure 5, A and B) . The preservation of bone mass in activated Ca V 1.2 TS mice after OVX was accompanied by maintenance of Tb.N and Tb.Sp compared with control sham mice ( Figure 5B ). Consistent with these data, we confirmed by H&E staining that OVX Ca V 1.2 TS mice maintained trabecular bone in femurs similar to control sham mice and stemmed trabecular bone loss compared with OVX control mice ( Figure 5C ). The maintenance of bone mass after OVX in the Ca V 1.2 TS -expressing bones was in part due to sustained osteoblast function, as dynamic histomorphometric analysis showed that BFR, MAR, and MS/BS were unaffected in Ca V 1.2 TS mutant femurs after OVX compared with control sham mice and were significantly higher than control OVX mice ( Figure 5, D and E) . ). BFR, bone formation rate; MAR, mineral apposite rate; and MS/BS, percentage of mineralizing surface over bone surface. Bar values are means ± SD (n ≥ 8. *P < 0.05 and **P < 0.01). Statistical analysis was performed by one-way ANOVA followed by Tukey's post-test analysis, and a P value less than 0.05 was considered significant.
Discussion
This study revealed unexpected roles for the Ca V 1.2 voltage-gated Ca 2+ channel in bone development and remodeling and uncovered consequences of increased Ca 2+ influx through the channels. Using conditional mouse models and the BMSC culture system, we demonstrated that expression of a transgenic Ca V 1.2 TS mutant channel promotes bone formation and inhibits bone resorption during skeletal development, homeostasis, and osteoporotic contexts. Actions of voltage-gated L-type Ca 2+ channels were previously reported in osteosarcoma cell lines (6, 8, 24) , and a previous immunohistochemical study suggested the presence of Ca V 1.2 in developing bones (25) . Our data, exploiting a definitive Ca V 1.2 signal from a mouse in which lacZ was knocked into the Cacna1c gene, reveal the endogenous Ca V 1.2 expression pattern and avoid nonspecific signals that can arise from detection by antibodies. With this approach, we observed prominent endogenous Ca V 1.2 expression in the developing perichondrium/periosteum, endosteum, and growth plate, which all give rise to osteoprogenitors. We did not detect Ca V 1.2 in the marrow cavity, as was suggested by one study using an immunohistochemical approach (25) but not by another (26) . Further, we observed the consequences of activating Ca V 1.2 TS expression in vivo. Thus, these data extend previous findings for a Ca V 1.2 role in mandibular development (4) Because these mouse models all employed Cre recombinases that drove Ca V 1.2 TS expression in osteoblast lineages, and not in osteoclasts or their precursors, we conclude that the observed anticatabolic responses resulted from an increase in the Rankl/Opg expression ratio and OPG secretion and consequent extrinsic inhibition of osteoclastogenesis. This is consistent with previous data showing that Ca V 1.2 regulates OPG secretion (27) and the well-defined roles for Ca V 1.2 channels in promoting hormone secretion from endocrine tissue. Moreover, our lacZ expression data showed that Ca V 1.2 is expressed within bone tissue where osteoblast precursor cells reside, and previous RNA-seq data showed no expression of Ca V 1.2 in murine BMMs or during osteoclast differentiation (15) TS suggests a possible therapeutic strategy for osteoporotic or osteopenic conditions. The majority of current osteoporosis treatments are anticatabolic agents that reduce osteoclast bone resorption, such as estrogens, bisphosphates, and calcitonin (30, 31) . These anticatabolics (especially bisphosphonates) are associated with gastrointestinal problems, osteonecrosis of the jaw, and atypical femur fractures or fragility fractures. Therefore, our approach here is more in line with anabolic therapies such as recombinant human parathyroid hormone (rhPTH) (32) and more recently developed agents demonstrating dual roles (e.g., romosozumab) that show increasing promise (33 Chemicals. All chemicals were obtained from MilliporeSigma unless otherwise indicated. X-gal staining. X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) staining was performed on frozen tissue sections. Forelimbs or hindlimbs were fixed in 4% paraformaldehyde on ice for 20 minutes (embryos) or 1 hour (postnatal stage), decalcified with 14% EDTA at 4°C, processed to 30% sucrose, and snap-frozen embedded with OCT compound (Sakura Finetek). Frozen sections (10 μm-thick) were refixed in ice-cold 1× PBS with 2% paraformaldehyde, 0.2% glutaraldehyde, 2 mM MgCl 2 , 0.2% Tween-20, and 30% sucrose for 10 minutes and stained with X-gal staining solution (5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 1 mg/ml X-gal, 2 mM MgCl 2 , 0.1% sodium deoxycholate, and 0.2% IGEPAL CA-630 in dark for 24-48 hours at 37°C. Specimens were counterstained with Nuclear Fast Red. For X-gal staining on BMSCs, the staining was performed for 48 hours at 37°C.
X-ray radiography and μCT analysis of mice. X-ray radiographic images of the hindlimbs were acquired using a Faxitron X-ray system (Faxitron Bioptics) at 31 kV for 9 seconds. For μCT scanning, the specimens were fixed in 10% neutral buffered formalin and then fitted in a 50 ml centrifuge tube with 70% ethanol. Images were obtained with a Scanco VivaCT 80 scanner (Scanco Medical AG) set to 55 kVp and 145 μA, voxel size 10.4 μm. To quantify trabecular bone parameters, 50 μCT slices (~0.5 mm total) immediately below the distal growth plate of the femur were analyzed.
Double labeling and cryosectioning. For dynamic histomorphometry, mice were injected i.p. with calcein and alizarin-3-methyliminodiacetic acid (MilliporeSigma) at 20 mg/kg and 40 mg/kg, respectively, on days 8 and 2 prior to euthanasia. Femurs were extracted and fixed in 10% neutral buffered formalin for 24 hours. After washing with 1× PBS, nondecalcified femurs were processed to 30% sucrose and OCT embedding, and they were sectioned at 10 μm using Leica Cryostat equipped with Cryojane (Leica). The slides were counterstained with DAPI. Dynamic histomorphometry was performed with OsteoMeasure commercial software.
Histology and TRAP staining. For histology, decalcified samples were processed for paraffin embedding and then sectioned at 6-μm thickness. H&E, ABH/OG, and TRAP staining were performed following standard protocols.
Mouse BMSC isolation and culture, viral infection, and osteoblast differentiation. BMSCs were isolated aseptically from the femurs and tibias of 6-to 10-week-old Rosa26-Ca V 1.2 TS or WT mice and were plated in α-MEM without ascorbic acid (Thermo Fisher Scientific) with 15% FBS (Hyclone) and 1% penicillin/ streptomycin (Invitrogen) at 37°C in a 5% CO 2 humidified incubator. After 48 hours of adhesion, the media was changed to remove nonadherent cells. BMSCs reached confluency after an additional 4 days of culture with a single media change. Cells were passaged with 0.25% trypsin-EDTA digestion (Invitrogen) and reseeded at 3 × 10 5 cells/6-well or 1 × 10 5 cells/12-well for mineralization assays.
